内地生物制药公司科济药业(02171.HK)公布招股详细，计划发行9,474.7万股，当中10%为本地发售，90%为国际配售，每股招股价介乎29.6至32.8元，集资最多约31.07亿元。每手500股入场费约16,565.26元，联席保荐人为高盛及瑞银。招股期由下周一(7日)起至下周四(10日)结束，料於6月18日上市。是次招股共引入9名基石投资者，包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金，合共认购约17.85亿元或2.3亿美元等值股份，设6个月禁售期。财务高级副总裁谢岚表示，由於公司尚未有产品商业化，因此过往几年录得经营亏损，去年度亏损达10.64亿元人民币，料於明年上半年就核心产品CT053提交中国新药上市申请。问到与热门新股时代天使(06699.HK)撞期，董事会主席、首席执行官兼首席科学官李宗海称，每家公司都有特点，投资者亦有不同关注重点，又指在研产品於临床实验中显示出有疗效及安全性，相信会得到市场认可。(gc/a)~阿思达克财经新闻网址: www.aastocks.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments